TRIANA Biomedicines
Tim Wigle serves as the Vice President of Lead Discovery at TRIANA Biomedicines since March 2022. Prior to this role, Tim held various senior positions at Ribon Therapeutics from February 2016 to March 2022, focusing on assay development for oncology drug discovery. Tim's experience includes leadership roles at Warp Drive Bio, LLC and Epizyme, where efforts were directed towards biochemistry and biophysics supporting drug discovery initiatives. Additionally, Tim has contributed to the field of chemical biology at UNC, with a focus on antibiotic resistance and epigenetics. Tim earned a PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill and a BSc in Biopharmaceutical Science/Chemistry from the University of Ottawa.
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.